染色体外与染色体内BRAF扩增在克服靶向治疗剂量挑战中的可塑性
该研究建立黑色素瘤双MAPK抑制剂(MAPKi)耐药模型,BRAFV600扩增经染色体外DNA(ecDNA)/双微体(DM)或染色体内同源染色区域(HSR)呈现。携带BRAFV600E局灶扩增的细胞在DM与HSR间切换,源于新发遗传改变与预存亚群选择;HSR细胞在剂量降低时出现药物成瘾驱动的BRAF扩增子结构丢失。
要点
- BRAFV600E局灶扩增细胞在DM与HSR间发生模式切换,源于新发遗传改变和预存亚群选择。
- 可塑性不限于ecDNA,HSR细胞在剂量降低时出现药物成瘾驱动的BRAF扩增子结构丢失。
- BRAF局灶扩增介导的双MAPKi耐药细胞对促铁死亡药物更敏感,扩展了耐药相关铁死亡敏感谱。
核心结论
- BRAF扩增在黑色素瘤MAPKi剂量挑战下高度可塑,涉及新发基因组改变,即使在HSR模式中也是如此。
- BRAF局灶扩增驱动的双MAPKi耐药细胞扩展了耐药相关铁死亡敏感谱。
研究设计与样本
- 建立黑色素瘤双MAPK抑制剂(MAPKi)耐药模型,其BRAFV600扩增通过染色体外DNA(ecDNA)/双微体(DM)或染色体内同源染色区域(HSR)实现。
主要发现
- 携带BRAFV600E局灶扩增的细胞在DM与HSR间发生模式切换,源于新发遗传改变和预存亚群选择。
- HSR细胞在剂量降低时出现药物成瘾驱动的BRAF扩增子结构丢失。
- 局灶扩增机制可与激酶结构域重复和可变剪接偶联以增强耐药。
- 药物响应性扩增子可塑性在临床中观察到,并可涉及其他MAPK通路基因如RAF1和NRAS。
- BRAF局灶扩增介导的双MAPKi耐药细胞对促铁死亡药物更敏感。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Focal amplifications (FA) can mediate targeted therapy resistance in cancer. Understanding the structure and dynamics of FAs is critical for designing treatments that overcome plasticity-mediated resistance. We developed a melanoma model of dual MAPK inhibitor (MAPKi) resistance that bears BRAFV600 amplifications through either extrachromosomal DNA (ecDNA)/double minutes (DM) or intrachromosomal homogenously staining regions (HSR). Cells harboring BRAFV600E FAs displayed mode switching between DMs and HSRs, from both de novo genetic changes and selection of preexisting subpopulations. Plasticity is not exclusive to ecDNAs, as cells harboring HSRs exhibit drug addiction-driven structural loss of BRAF amplicons upon dose reduction. FA mechanisms can couple with kinase domain duplications and alternative splicing to enhance resistance. Drug-responsive amplicon plasticity is observed in the clinic and can involve other MAPK pathway genes, such as RAF1 and NRAS. BRAF FA-mediated dual MAPKi-resistant cells are more sensitive to proferroptotic drugs, extending the spectrum of ferroptosis sensitivity in MAPKi resistance beyond cases of dedifferentiation. SIGNIFICANCE: Understanding the structure and dynamics of oncogene amplifications is critical for overcoming tumor relapse. BRAF amplifications are highly plastic under MAPKi dosage challenges in melanoma, through involvement of de novo genomic alterations, even in the HSR mode. Moreover, BRAF FA-driven, dual MAPKi-resistant cells extend the spectrum of resistance-linked ferroptosis sensitivity. This article is highlighted in the In This Issue feature, p. 873.
引用
- Song K, Minami JK, Huang A, et al. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges. Cancer Discov. 2022. PMID: 34930786. doi:10.1158/2159-8290.CD-20-0936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。